Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Tokmanni Group Corporation: Managers' Transactions – Tapio Arimo

Tokmanni Group Corporation        Managers' Transactions        8 April 2024 at 9:20 amPerson subject to the notification requirementName: Tapio ArimoPosition: Chief Financial OfficerIssuer: Tokmanni Group OyjLEI: 743700VMG6KWF0FW1560Notification type: INITIAL NOTIFICATIONReference number: 57578/5/4 Transaction date: 2024-03-22Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000197934Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 1491 Unit price: 0 EUR Aggregated transactions (1):Volume: 1491 Volume

Tokmanni Group Corporation: Managers' Transactions – Mika Rautiainen

Tokmanni Group Corporation        Managers' Transactions        8 April 2024 at 9:10 amPerson subject to the notification requirementName: Mika RautiainenPosition: Chief Executive OfficerIssuer: Tokmanni Group OyjLEI: 743700VMG6KWF0FW1560Notification type: INITIAL NOTIFICATIONReference number: 57575/4/4 Transaction date: 2024-03-22Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI4000197934Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 4821 Unit price: 0 EUR Aggregated transactions (1):Volume: 4821

Approval of Warrant Terms and Conditions

Faron Pharmaceuticals Oy(“Faron” or “Company”)   Approval of Warrant Terms and Conditions   Company announcement, April 8, 2024 at 12:10 AM (EDT) / 7:10 AM (BST) / 9:10 AM (EEST)   TURKU, FINLAND / BOSTON, MA - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announces that the Board of Directors of Faron has approved the terms and conditions of the remaining 832,934

Decisions of the Board of Directors

Faron Pharmaceuticals Oy (“Faron or the “Company”) Decisions of the Board of Directors Company announcement, April 8, 2024 at 9:05 (EEST) / 7:05 AM (GMT) / 12:05 AM (EDT)   TURKU, FINLAND / BOSTON, MA - The annual general meeting ("AGM") of Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON) took place on April 5, 2024 and after the AGM, the Board of Directors ("Board") convened.   Frank Armstrong and Erik Ostrowsi did not stand for re-election and thus their tenure in the Company Board of Directors ended at the end of the AGM on 5 April, 2024.   At the meeting

AFRY awarded a new large-scale solar power assignment in the Philippines

Amatera Renewable Energy Corporation has appointed AFRY as the owner’s engineer for the construction of a 65MWp solar photovoltaic (PV) plant and its electrical interconnection. The project will provide clean energy to the City of Bacolod in the Philippines.Amatera Renewable Energy Corporation (ARECO) is a Philippine-based company undertaking a utility-scale solar power project called The Vista Alegre, a ground-mounted solar PV installation that will be located in Bacolod, the capital city of the island of Negros. ARECO is now part of B.Grimm Solar Power Inc., a subsidiary of B.Grimm Power,

Richard Sjöberg new Head of Communications at AcadeMedia

Richard Sjöberg has been appointed Head of Communications and member of the executive management team at AcadeMedia. He will assume the position on 15 April 2024. - Communication is important for an education company like AcadeMedia, where the work we do every day affects and engages many people. Welcoming Richard to AcadeMedia and Group Management is part of our efforts to strengthen our communication. We strive to be a strong and wise voice that can help shape solutions to challenges facing the education sector. Richard's experience and expertise will be very valuable in this work,

Enhertu approved in US for HER2+ solid tumours

08 April 2024 Enhertu approved in the US as first tumour-agnostic HER2-directed therapyfor previously treated patients with metastatic HER2-positive solid tumours Based on three Phase II trials of AstraZeneca and Daiichi Sankyo's Enhertu which showedclinically meaningful responses across a broad range of tumours Enhertu now has five approved indications with the latest in HER2-expressing(IHC 3+) metastatic cancers AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic

Net Asset Value(s)

RIZE SUSTAINABLE FUTURE OF FOOD UCITS ETF (LEI: 635400XEUXEEYJDGAN37) Final Net Asset Value FUND NAME NAV ISIN NAV DATE RIZE SUSTAINABLE 3.9989 USD IE00BLRPQH01 05 April 2024FUTURE OF FOOD UCITS ETF RIZE CYBER SECURITY AND DATA PRIVACY UCITS ETF (LEI: 635400X9AIBDQQ6PQR51) Final Net Asset Value FUND NAME NAV­ ISIN NAV DATERIZE CYBER SECURITY AND 7.3671 USD IE00BJXRZJ40 05 April 2024DATA PRIVACY UCITS ETF RIZE DIGITAL PAY ECONOMY ETF (LEI: LEI 635400LYAWYIKLU7RN49) Final

Application submitted to include an additional terbinafine supplier

STOCKHOLM, April 8[th], 2024, Moberg Pharma AB (OMX:MOB) has submitted an application to include the proposed terbinafine supplier in the company's registration dossier for its nail fungus drug MOB-015. Approval is expected before the end of the year.Together with its intended terbinafine supplier, Moberg Pharma has submitted an application to add the manufacturer for MOB-015. In addition, Moberg Pharma is actively working to secure an additional terbinafine supplier and thus has two parallel tracks to ensure a stable long-term supply of terbinafine. "The submission of the application to

Getinge invites fund managers, analysts, and media to Q1 Report 2024 conference call

Getinge will issue its Q1 Report 2024 on April 22, 2024, at 12:00 p.m. CEST, followed by a conference call at 13:00-14.00 p.m. CEST, hosted by Mattias Perjos, President & CEO, and Agneta Palmér, CFO.Fund managers, analysts and media are invited to participate in the conference call. To participate via teleconference, please register via this link . After registration, you will be provided with telephone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.

The subscription period in Diagonal Bio AB rights issue commences today

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE. Today, the 8[th] of April 2024, the subscription period in Diagonal Bio AB’s ("Diagonal Bio" or "the Company") issue of units consisting of shares

Read original

InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2023

April 8, 2024 – InDex Pharmaceuticals Holding AB (publ) today publishes the Annual Report for 2023. The Annual Report is attached as a PDF and is available on the company’s website, https://www.indexpharma.com/en/financial-reports/.The Annual Report is mailed to shareholders and other stakeholders who specifically request it. Send request to info@indexpharma.com, or by mail to InDex Pharmaceuticals Holding AB (publ), Berzelius väg 13, 171 65 Solna, Sweden. For more information:Jenny Sundqvist, CEOPhone: +46 8 122 038 50E-mail: jenny.sundqvist@indexpharma.com Johan Giléus, CFO

Transaction in Own Shares

    08 April 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |05/04/2024|+-------------------------------------------------------------

Balder publishes Annual and Sustainability Report 2023

Fastighets AB Balder has summarised the fiscal year of 2023. The Annual and Sustainability Report, providing an overview of the group's progress towards financial and sustainability goals, is now available on the company's website.With a diversified property portfolio and high adaptability as a foundation, Balder consistently works broadly and purposefully to stand resilient. This was also the case in 2023. “2023 was in many ways similar to 2022. There is still turmoil in the external environment, contributing to continued global uncertainty. As a company, we are constantly adapting to

Hexagon appoints Maria Luthström and Gordon Dale as joint Presidents of its Autonomous Solutions division

Hexagon AB, the global leader in digital reality solutions, combining sensor, software and autonomous technologies, today announced the appointment of Maria Luthström and Gordon Dale as joint Presidents of the Autonomous Solutions (AS) division, effective 1 May 2024. Both will join the Hexagon Executive Management team, reporting directly to Paolo Guglielmini, President and CEO, Hexagon. Michael Ritter, the current President of AS, will retire at the end of 2024 following a transition period. AS, launched in 2022, combined the Autonomy & Positioning (A&P) and Mining divisions. A&P

Cost savings target increased to more than US$30m per annum and entry into definitive transaction agreement for the sale of Koffiefontein.

8 April 2024 LSE: PDL   Petra Diamonds Limited (Petra, the Company or the Group)   Cost savings target increased to more than US$30m per annum and entry into definitive transaction agreement for the sale of Koffiefontein   In line with its approach to building business resilience, Petra announces additional steps to reduce costs and provides an update of the sale of its interest in the Koffiefontein Diamond Mine (KDM).   Richard Duffy, Petra’s Chief Executive Officer, said:   “We remain on track to deliver the US$75 million of cash savings in FY

Notification according to chapter 9, section 5 and 6 of the Securities Market Act: BlackRock Inc.’s holding in Metso

Metso Corporation’s stock exchange release on April 8, 2024, at 9:00 a.m. EESTMetso Corporation has received a notification, pursuant to Chapter 9, Section 5 and 6 of the Finnish Securities Markets Act, about a change in the shareholding of BlackRock, Inc. On April 4, 2024, BlackRock's holding in Metso’s shares fell below the 5 percent threshold and amounted to 40,613,809 shares or 4.89 percent of total shares and votes. BlackRock's holding through financial instruments in Metso amounted to 1,892,210 shares, which corresponds to 0.22 percent of the total amount of Metso’s shares. On

Nanoform Finland Plc: Certified Adviser change to Carnegie Investment Bank Ab

Company release Nanoform Finland Plc April 8, 2024 09.00 Finnish time / 08.00 Swedish time Nanoform Finland Plc: Certified Adviser change to Carnegie Investment Bank Ab The shares of Nanoform Finland Plc are listed for trading on Nasdaq First North Premier Growth Market Finland maintained by Nasdaq Helsinki Ltd and Nasdaq First North Premier Growth Market Sweden maintained by Nasdaq Stockholm Ltd, which require the nomination of a Certified Adviser. Effective April 10, 2024, the Certified Adviser to Nanoform Finland Plc is Carnegie Investment Bank Ab (publ). The Certified

Repurchase of Loomis’ shares completed

Loomis AB has through the repurchase program that was resolved and communicated on January 30, 2024 repurchased 700,000 shares. Loomis AB’s holding of own shares thereby amounts to 4,908,782 shares, corresponding to 6.52% of the outstanding shares in the company. The total number of shares in Loomis AB, including the company's own shares, amounts to 75,279,829. For information about transactions in the repurchase program, please see: www.nasdaqomxnordic.com/news/corporate-actions/repurchase-of-own-shares. This press release is also available on the company's website, www.loomis.com.

Africa Oil Announces Results of Share Buyback Program

VANCOUVER, BC, April 8, 2024 /CNW/ - (AOI–TSX, AOI–Nasdaq-Stockholm) – Africa Oil Corp. (“Africa Oil”, or the “Company”) is pleased to announce that the Company repurchased a total of 1,050,800 Africa Oil common shares during the period of April 1, 2024 to April 5, 2024 under the previously announced share buyback program. The launch of Africa Oil’s normal course issuer bid (share buyback) program, announced by the Company on December 4, 2023, is being implemented in accordance with the Market Abuse Regulation (EU) No 596/2014 (MAR) and Commission Delegated Regulation (EU) No 2016/1052 (

Appointment of Chief Executive Officer

Faron Pharmaceuticals Oy   (“Faron or the “Company”)   Appointment of Chief Executive Officer     Company announcement, April 8, 2024 at 9:00 (EEST) / 7:00 AM (BST) / 2:00 AM (EDT)     TURKU, FINLAND / BOSTON, MA – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announces that its Chief Executive Officer (CEO) Dr. Markku Jalkanen, who turns 70 later in 2024, has

Invitation to presentation of Careium’s first quarter report 2024

Careium will publish its first quarter report 2024 on April 25, 2024 at 8am (CEST). A live broadcast report presentation will be held at 10am (CEST) on the same day where CEO Christian Walén will present the report and answer questions.The presentation will be webcast and can be accessed at the following link.https://www.youtube.com/watch?v=w-yZlVxP2VA  The presentation will be available on https://www.careium.com/en-gb/investors/financial-information/presentations2/ after the live broadcast.

Humana acquires Team Olivia Norge AS

Humana Group ("Humana") strengthens its offering of high-quality care services in Norway as Human Care Holding AS ("Humana Norway") has entered into an agreement to acquire Team Olivia Norge AS ("the Transaction") for a purchase price of million SEK 341 on a cash- and debt-free basis. The acquisition is partially financed through an issue in kind of 4 million shares to the sellers[1)]. The acquisition is expected to contribute to a reduced operational risk through a more diversified customer base and broader geographical exposure. The Transaction is expected to make the Norway business area

NCC to conduct construction work for SSAB in Oxelösund

NCC has been commissioned by SSAB to conduct initial work for a new facility in Oxelösund. The project is a construction contract in partnering form with an order value of approximately SEK 200 million. SSAB Oxelösund_Foto SSAB  Initially NCC has partnered with SSAB on production planning and scheduling and on producing cost estimates for the new facility. The ground and foundation engineering work for the facility are now commencing. The order value for the initial work is approximately SEK 200 million and is registered in the NCC Building Sweden business area in the first

There are no items matching the current filter
There are no more items matching the current filter
Back to top